Aditxt Inc. (NASDAQ:ADTX) — Market Cap & Net Worth
Market Cap & Net Worth: Aditxt Inc. (ADTX)
Aditxt Inc. (NASDAQ:ADTX) has a market capitalization of $2.12K ($2.12K) as of August 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31774 globally and #6284 in its home market, demonstrating a -25.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aditxt Inc. 's stock price $0.00 by its total outstanding shares 815921 (815.92K). Review cash generation quality of Aditxt Inc. to assess how much free cash flow the company generates relative to operating cash flow.
Aditxt Inc. Market Cap History: 2020 to 2026
Aditxt Inc. 's market capitalization history from 2020 to 2026. Data shows change from $67.88 Million to $2.12K (-84.28% CAGR).
Index Memberships
Aditxt Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #930 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2924 of 3165 |
Weight: Aditxt Inc. 's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aditxt Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aditxt Inc. 's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
213.11x
Aditxt Inc. 's market cap is 213.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $17.50 Million | $105.03K | -$46.37 Million | 166.58x | N/A |
| 2022 | $37.68 Million | $933.72K | -$27.65 Million | 40.36x | N/A |
| 2023 | $216.38 Million | $645.18K | -$32.38 Million | 335.38x | N/A |
| 2024 | $154.86K | $133.99K | -$34.45 Million | 1.16x | N/A |
| 2025 | $680.89K | $3.19K | -$41.71 Million | 213.11x | N/A |
Competitor Companies of ADTX by Market Capitalization
Companies near Aditxt Inc. in the global market cap rankings as of August 2, 2026.
Key companies related to Aditxt Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Aditxt Inc. Historical Marketcap From 2020 to 2026
Between 2020 and today, Aditxt Inc. 's market cap moved from $67.88 Million to $ 2.12K, with a yearly change of -84.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.12K | -99.69% |
| 2025 | $680.89K | +339.67% |
| 2024 | $154.86K | -99.93% |
| 2023 | $216.38 Million | +474.22% |
| 2022 | $37.68 Million | +115.37% |
| 2021 | $17.50 Million | -74.23% |
| 2020 | $67.88 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Aditxt Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.12K USD |
| MoneyControl | $2.12K USD |
| MarketWatch | $2.12K USD |
| marketcap.company | $2.12K USD |
| Reuters | $2.12K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aditxt Inc.
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body nat… Read more